L&G Pharma Breakthrough UCITS ETF (BIGT.L)
BIGT.L is a passive ETF by Legal & General tracking the investment results of the NASDAQ Biotechnology TR USD. BIGT.L launched on Jan 18, 2018 and has a 0.49% expense ratio.
ETF Info
| ISIN | IE00BF0H7608 |
|---|---|
| WKN | A2H9XR |
| Issuer | Legal & General |
| Inception Date | Jan 18, 2018 |
| Category | Health & Biotech Equities |
| Index Tracked | NASDAQ Biotechnology TR USD |
| Domicile | Ireland |
| Distribution Policy | Accumulating |
| Asset Class | Equity |
Asset Class Size | Mid-Cap |
Asset Class Style | Growth |
Expense Ratio
BIGT.L has a high expense ratio of 0.49%, indicating higher-than-average management fees.
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in L&G Pharma Breakthrough UCITS ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
L&G Pharma Breakthrough UCITS ETF had a return of -6.46% year-to-date (YTD) and -15.87% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -6.46% | 7.50% |
| 1 month | 0.87% | -1.61% |
| 6 months | -4.37% | 17.65% |
| 1 year | -15.87% | 26.26% |
| 5 years (annualized) | 0.96% | 11.73% |
| 10 years (annualized) | N/A | 10.64% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -4.74% | -0.47% | 0.24% | -4.88% | ||||||||
| 2023 | -6.96% | 2.54% | 2.68% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of BIGT.L is 1, indicating that it is in the bottom 1% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
L&G Pharma Breakthrough UCITS ETF(BIGT.L)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for L&G Pharma Breakthrough UCITS ETF (BIGT.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the L&G Pharma Breakthrough UCITS ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the L&G Pharma Breakthrough UCITS ETF was 28.12%, occurring on Apr 18, 2024. The portfolio has not yet recovered.
The current L&G Pharma Breakthrough UCITS ETF drawdown is 23.99%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -28.12% | Feb 7, 2023 | 302 | Apr 18, 2024 | — | — | — |
| -21.77% | Sep 4, 2018 | 80 | Dec 24, 2018 | 293 | Feb 21, 2020 | 373 |
| -20.63% | Nov 12, 2021 | 146 | Jun 16, 2022 | 161 | Feb 3, 2023 | 307 |
| -19.69% | Feb 24, 2020 | 15 | Mar 13, 2020 | 27 | Apr 23, 2020 | 42 |
| -13.09% | Feb 12, 2021 | 16 | Mar 5, 2021 | 169 | Nov 4, 2021 | 185 |
Volatility
Volatility Chart
The current L&G Pharma Breakthrough UCITS ETF volatility is 4.50%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.